Lymphedema is an accumulation of fluid due to disruption of lymphatic drainage. Lymphedema can be caused by congenital or inherited abnormalities in the lymphatic system (primary lymphedema), but is most often caused by acquired damage to the lymphatic system (secondary lymphedema). Breast cancer treatment is one of the most common causes of secondary lymphedema. Both the surgical removal of lymph nodes and radiotherapy are associated with the development of lymphedema in individuals with breast cancer.
Physiological microsurgical techniques have been developed in an effort to improve lymphatic circulation and thereby decrease symptoms and risk of infection. These surgical interventions can be broadly grouped into two procedures:
Reconstruct or bypass the obstructed lymphatic vessels to improve lymphatic drainage (lymphatico-lymphatic bypass, lymphovenous bypass and lymphaticovenular anastomosis)
Preventative lymphaticovenular anastomosis is performed during nodal dissection or reconstructive surgery and involves anastomosing arm lymphatics to a collateral branch of an axillary vein. This procedure is also known as the Lymphatic Microsurgical Preventing Healing Approach (LYMPHA).
Transfer lymph tissue into an obstructed area to reestablish lymphatic flow (autologous lymph node transplantation and vascularized lymph node transfer).
Lymphatic physiologic microsurgery for the treatment of breast cancer-related lymphedema, including, but not limited to, the following is considered investigational:
Autologous lymph node transplantation
Vascularized lymph node transfer
Lymphatic physiologic microsurgery performed during nodal dissection or breast reconstruction for the prevention of breast cancer-related lymphedema, including, but not limited to, lymphaticovenular anastomosis (Lymphatic Microsurgical Preventing Healing Approach [LYMPHA]) is considered investigational.
Any specific products referenced in this policy are just examples and are intended for illustrative purposes only. It is not intended to be a recommendation of one product over another, and is not intended to represent a complete listing of all products available. These examples are contained in the parenthetical e.g. statement.
We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, or explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the Medical Policy and a health plan, the express terms of the health plan will govern.
There is a lack of high-quality evidence published in peer-reviewed journals to evaluate the effectiveness of this technology on health outcomes.
BlueCross BlueShield Association. Evidence Positioning System. (7:2018). Surgical treatments for breast cancer-related lymphedema (7.01.162). Retrieved October 15, 2018 from https://www.evidencepositioningsystem.com/. (23 articles and/or guidelines reviewed)
Cornelissen, A.J.M., Beugels, J., Ewalds, L., Heuts, E.M., Keuter, X.H.A., Piatkowski, A., et al. (2018). The effect of lymphaticovenous anastomosis in breast cancer-related lymphedema: a review of the literature. Lymphatic Research and Biology, 2018 Jan 22. Doi: 10.1089/lrb.2017.0067. [Epub ahead of print]. Abstract retrieved October 16, 2018 from PubMed database.
Demiri, E., Dionyssiou, D., Tsimponis, A., Goula, O.C., Milothridis, P., Pavilidis, L., et al. (2018). Donor-site lymphedema following lymph node transfer for breast cancer-related lymphedema: a systematic review of the literature. Lymphatic Research and Biology, 16 (1), 2-8. Abstract retrieved October 16, 2018 from PubMed database.
Dionyssiou, D., Demiri, E., Tsimponis, A., Sarafis, A., Mpalaris, V., Tatsidou, G., & Arsos, G. (2016). A randomized control study of treating secondary stage II breast cancer-related lymphoedema with free lymph node transfer. Breast Cancer Research and Treatment, 156 (1), 73-79. Abstract retrieved October 16, 2018 from PubMed database.
Jørgensen, M.G., Touserkani, N.M., & Sørensen, J.A. (2017). The effect of prophylactic lymphovenous anastomosis and shunts for preventing cancer-related lymphedema: a systematic review and meta-analysis. Microsurgery, 2017 Mar 28. Doi: 10.1002/micr.30180. [Epub ahead of print].
Nguyen, A.T., Suami, H., Hanasono, M.M., Womack, V.A., Wong, F.C., & Chang, E.I. (2017). Long-term outcomes of the minimally invasive free vascularized omental lymphatic flap for the treatment of lymphedema. Journal of Surgical Oncology, 115 (1), 84-89. Abstract retrieved October 16, 2018 from PubMed database.
Scaglioni, M.F., Arvanitakis, M., Chen, Y.C., Giovanoli, P., Chia-Shen Yang, J., & Chang, E. (2018). Comprehensive review of vascularized lymph node transfers for lymphedema: outcomes and complications. Microsurgery, 38 (2), 222-229. Abstract retrieved October 16, 2018 from PubMed database.
Scaglioni, M.F., Fontein, D.B.Y., Arvanitakis, M., & Giovanoli, P. (2017). Systematic review of lymphovenous anastomosis (LVA) for the treatment of lymphedema. Microsurgery, 37 (8), 947-953. Abstract retrieved October 16, 2018 from PubMed database.
Winifred S. Hayes, Inc. Medical Technology Directory. (2017 May; last update search May 2018). Surgical treatment of lymphedema: a review of reviews. Retrieved October 16, 2018 from www.Hayesinc.com/subscribers. (20 articles and/or guidelines reviewed)
ORIGINAL EFFECTIVE DATE: 3/2/2019
MOST RECENT REVIEW DATE: 3/2/2019
Policies included in the Medical Policy Manual are not intended to certify coverage availability. They are medical determinations about a particular technology, service, drug, etc. While a policy or technology may be medically necessary, it could be excluded in a member's benefit plan. Please check with the appropriate claims department to determine if the service in question is a covered service under a particular benefit plan. Use of the Medical Policy Manual is not intended to replace independent medical judgment for treatment of individuals. The content on this Web site is not intended to be a substitute for professional medical advice in any way. Always seek the advice of your physician or other qualified health care provider if you have questions regarding a medical condition or treatment.
This document has been classified as public information.